Cline Scientific receives Notice of Allowance for StemCART in Europe

This notice of upcoming approval (Notice of Allowance) means that the EPO intends to grant the Company's patent application. Once granted, which is anticipated late Q2 or early Q3, Cline can choose which of the 39 EPO member states in which to uphold the patent. 

More about StemCART
StemCART is a preclinical Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. 

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088

 

Datum 2023-04-12, kl 14:42
Källa Cision
Bifogade filer
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.